{
    "nctId": "NCT02207361",
    "briefTitle": "Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer",
    "officialTitle": "A Randomized Prospective Clinical Trial of Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin as First-Line Treatment in Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "RECIST 1.1",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female \u2265 18 years old, ECOG 0-2 or KPS\u226560, Expected lifetime more than 12 weeks.\n\nExclusion Criteria:\n\n* Pregnancy, Paclitaxel, platinum and anthracycline-based drugs' allergy, Severe Infection.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}